These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

50 related items for PubMed ID: 2274638

  • 1. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients.
    Alpert M, Allan ER, Citrome L, Laury G, Sison C, Sudilovsky A.
    Psychopharmacol Bull; 1990; 26(3):367-71. PubMed ID: 2274638
    [Abstract] [Full Text] [Related]

  • 2. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study.
    Ratey JJ, Sorgi P, O'Driscoll GA, Sands S, Daehler ML, Fletcher JR, Kadish W, Spruiell G, Polakoff S, Lindem KJ.
    J Clin Psychiatry; 1992 Feb; 53(2):41-6. PubMed ID: 1347291
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
    Buckley PF.
    Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
    [Abstract] [Full Text] [Related]

  • 5. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients.
    Allan ER, Alpert M, Sison CE, Citrome L, Laury G, Berman I.
    J Clin Psychiatry; 1996 Oct; 57(10):455-9. PubMed ID: 8909331
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R.
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [Abstract] [Full Text] [Related]

  • 7. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J, Deramciclane Dose-Finding Study Group.
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [Abstract] [Full Text] [Related]

  • 8. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
    Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G.
    Mov Disord; 2005 Aug; 20(8):958-63. PubMed ID: 15800937
    [Abstract] [Full Text] [Related]

  • 9. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ, Riedel M, Müller N, Fischer W, Kohnen R.
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [Abstract] [Full Text] [Related]

  • 10. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 11. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial.
    Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M.
    Bipolar Disord; 2006 Oct; 8(5 Pt 1):485-9. PubMed ID: 17042886
    [Abstract] [Full Text] [Related]

  • 12. A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania.
    Eden Evins A, Demopulos C, Nierenberg A, Culhane MA, Eisner L, Sachs G.
    Bipolar Disord; 2006 Feb; 8(1):75-80. PubMed ID: 16411983
    [Abstract] [Full Text] [Related]

  • 13. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A.
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [Abstract] [Full Text] [Related]

  • 14. Predictors of violent behavior among acute psychiatric patients: clinical study.
    Amore M, Menchetti M, Tonti C, Scarlatti F, Lundgren E, Esposito W, Berardi D.
    Psychiatry Clin Neurosci; 2008 Jun; 62(3):247-55. PubMed ID: 18588583
    [Abstract] [Full Text] [Related]

  • 15. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
    Roth T, White D, Schmidt-Nowara W, Wesnes KA, Niebler G, Arora S, Black J.
    Clin Ther; 2006 May; 28(5):689-706. PubMed ID: 16861091
    [Abstract] [Full Text] [Related]

  • 16. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
    Nasrallah HA, Brecher M, Paulsson B.
    Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
    Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR, BOLDER II Study Group.
    J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817
    [Abstract] [Full Text] [Related]

  • 18. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P.
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [Abstract] [Full Text] [Related]

  • 19. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [Abstract] [Full Text] [Related]

  • 20. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics.
    Martinotti G, Andreoli S, Di Nicola M, Di Giannantonio M, Sarchiapone M, Janiri L.
    Hum Psychopharmacol; 2008 Jul; 23(5):417-24. PubMed ID: 18425995
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.